An unfavourable prognosis for pancreatic cancer indicates fields of opportunity

Greenhalf, W.
November 2006
Gut;Nov2006, Vol. 55 Issue 11, p1533
Academic Journal
The author reflects on the study conducted by J. Kim, H. A. Reber and S. M. Dry about critical prognosis for pancreatic cancer. He states that the research represents the trend which has based that the disease can no longer be considered an incurable in all cases. Furthermore, he comments that the adjuvant radiotherapy seems to be less effective in patient survival than general chemotherapy.


Related Articles

  • Extended pancreatectomy for pancreatic cancers. Shukla, Parul; Sakpal, Sujit // Indian Journal of Surgery;Feb2009, Vol. 71 Issue 1, p2 

    Pancreatic cancer carries a poor prognosis. A minority of patients are considered for surgical excision. Local extension, lymph node metastasis, poor prognosis with distal spread and the lack of effectiveness of chemo and radiotherapy, have led to a nihilistic approach to this disease. This...

  • Randomized phase II -- study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer -- PARC: study protocol [ISRCTN56652283]. Krempien, R.; Muenter, M. W.; Huber, P. E.; Nill, S.; Friess, H.; Timke, C.; Didinger, B.; Buechler, P.; S.Heeger; Herfarth, K. K.; Abdollahi, A.; Buchler, M. W.; Debus, J. // BMC Cancer;2005, Vol. 5, p131 

    Background: Pancreatic cancer is the fourth commonest cause of death from cancer in men and women. Advantages in surgical techniques, radiation therapy techniques, chemotherapeutic regimes, and different combined-modality approaches have yielded only a modest impact on the prognosis of patients...

  • Gemcitabine plus radiation improved OS in pancreatic cancer.  // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p18 

    The article focuses on a study by researchers from the Eastern Cooperative Oncology Group (ECOG) which revealed the efficacy of the combination of gemcitabine and radiation therapy for patients with localized unresectable pancreatic cancer when compared with chemotherapy alone. The researchers...

  • Pancreatic cancer patients fare better with hyperthermia.  // Medical Device Daily;10/14/2011, Vol. 15 Issue 197, p1 

    The article reports on an open-label, comparative cohort study of 60 patients suffering from locally advanced, unresectable pancreatic cancer (LAPC) conducted by researchers from the University Hospital of Verona. It found that patients treated with hyperthermia using the BSD-2000 Hyperthermia...

  • Nucleosomes in Pancreatic Cancer Patients during Radiochemotherapy. Kremer, Andreas; Wilkowski, Ralf; Holdenrieder, Stefan; Nagel, Dorothea; Stieber, Petra; Seidel, Dietrich // Tumor Biology;Jan/Feb2005, Vol. 26 Issue 1, p44 

    Nucleosomes appear spontaneously in elevated concentrations in the serum of patients with malignant diseases as well as during chemo- and radiotherapy. We analyzed whether their kinetics show typical characteristics during radiochemotherapy and enable an early estimation of therapy efficacy. We...

  • “Aggressive” Operations for Pancreatic Cancer: Technical and Biologic Challenges. Espat, N. // World Journal of Surgery;Jun2006, Vol. 30 Issue 6, p983 

    The author focuses on the prognosis and progression to death for patients with advance stage pancreatic cancer. It was observed that there is minimal incremental improvement in the overall survival noted with the emergence of modern chemotherapy strategies. The role and utility of chemotherapy...

  • Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Goldstein, D.; Van Hazel, G.; Walpole, E.; Underhill, C.; Kotasek, D.; Michael, M.; Shapiro, J.; Davies, T.; Reece, W.; Harvey, J.; Spry, N. // British Journal of Cancer;8/20/2007, Vol. 97 Issue 4, p464 

    The aim of this phase II study was to assess the feasibility and efficacy of a specific three-dimensional conformal radiotherapy technique with concurrent continuous infusion of 5-fluorouracil (CI 5FU) sandwiched between gemcitabine chemotherapy in patients with locally advanced pancreatic...

  • A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Ueno, H.; Kosuge, T.; Matsuyama, Y.; Yamamoto, J.; Nakao, A.; Egawa, S.; Doi, R.; Monden, M.; Hatori, T.; Tanaka, M.; Shimada, M.; Kanemitsu, K. // British Journal of Cancer;9/8/2009, Vol. 101 Issue 6, p908 

    Background:This multicentre randomised phase III trial was designed to determine whether adjuvant chemotherapy with gemcitabine improves the outcomes of patients with resected pancreatic cancer.Methods:Eligibility criteria included macroscopically curative resection of invasive ductal carcinoma...

  • Drug resistance: Getting through. McCarthy, Nicola // Nature Reviews Cancer;Jul2009, Vol. 9 Issue 7, p458 

    The article discusses the factors that affect the prognosis in patients with pancreatic ductal adenocarcinoma (PDA). It notes on the study by Kenneth Olive, David Tuveson, and colleagues that found the molecular changes in tumor cells were not responsible for drug resistance. It implies that PDA...


Read the Article


Sign out of this library

Other Topics